

# Improving patient care with AI-powered cancer treatment diagnostics.

Founded in 2018, DoMore Diagnostics has developed a deep-learning precision diagnostics solution that guides oncologists in choosing the best patient treatment path after cancer removal surgery. DoMore Diagnostics is currently leading in colorectal and gastrointestinal cancers.

domorediagnostics

Net impact value creation in 2023 (USD) 1

\$ 0.03 M

Impact potential


5/5 – Impact-generating

#### The problem

Cancer rates are set to increase by 70% by 2050. However, many patients still receive inappropriate or futile cancer treatment due to inaccurate cancer prognosis methods, resulting in economic costs to society and a significant human cost for individuals. In addition, workforce shortage reduces the time specialists can spend on each patient's prognosis.

### The change we need

DoMore's digital pathology technology uses deep learning to enable more accurate colorectal cancer prognosis and better assess if further treatment is beneficial. Fewer patients receive unnecessary treatment, treatment costs decrease, and cancer specialists can treat cases more efficiently in the current context of workforce shortage.



<sup>1</sup> Using data from the Upright Project and applying Norselab's custom value mapped to the SDGs. Read more about this metric on page 21. Norselab owns 33% of the company and has therefore contributed to 33% of this impact value creation.

## DoMore's impact metrics

## DoMore's impact contribution

1,084 1,122 in 2022

1,084 patients for which the product tests have been validated.



Life on land

Target 3.4

DoMore Diagnostics enables more precise cancer prognosis and treatment. A number of patients can avoid receiving damaging treatment that would bring no benefits.

1

1 approved patent.